News in Press-centre

The construction of the newest research apparatus on Russky Island for studying molecular structures—synchrotron—will enable scientists of Far Eastern Federal University (FEFU) to deepen research in physics, biology, medicine, and the creation of new materials. At present, there are several research teams at FEFU, whose work can reach a new level due to the use of synchrotron. This was announced by Alexander Molochkov, the Head of the Center for Chiral Biophotonics of the FEFU School of Biomedicine. 

“Synchrotron centers are part of the modern scientific infrastructure. They help solve different tasks of fundamental and applied nature in the field of solid state physics, new materials, biology, and medicine. For us, this opens prospects for the development of research at a qualitatively higher level, gives the possibility to organize modern technopark of accelerating technologies around the synchrotron,” said Alexander Molochkov, DSc (Phys. & Math.).

The scientist said that the construction of such installations on Russky Island would take between three to five years. One of the most likely options is the construction of a synchrotron with a source of terahertz radiation. Such idea is being discussed with FEFU partners from RIKEN International Science and Technology Center (Japan), Uppsala University, and Stockholm University (Sweden).

Terahertz radiation is between the infrared and microwave bands. Such an installation will help to explore the properties of new quantum materials, processes responsible for the fundamental mechanisms of living cells, and create new materials for ultrafast information processing.

FEFU has developed a base for such studies in recent years. Research groups have emerged that deal with magnetic materials and new magnetic memory elements. A deepwater research project is being actively developed. By using the synchrotron one can explore new biopolymers, discovered while researching deep-sea organisms. This would solve many of pharmacological and biomedical challenges in the field of neurodegenerative diseases and oncology.